How do we manage t(11;14) plasma cell disorders with venetoclax?
- 20 May 2022
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 199 (1) , 31-39
Abstract
Summary: The oral BCL‐2 inhibitor venetoclax has demonstrated promising efficacy in patients with t(11;14) plasma cell disorders, both as a single‐agent and in combination. However, there was an increased mortality signal in the randomized BELLINI trial that was primarily driven by non‐t(11;14) patients. Based on current evidence, venetoclax is included as an option for relapsed/refractory t(11;14) plasma cell dyscrasias in NCCN guidelines and is being widely used in clinical practice. In this review, we aim to critically appraise the current literature and perform case‐based illustration of our approach to management of t(11;14) plasma cell disorders with venetoclax.Keywords
This publication has 42 references indexed in Scilit:
- Natural history of t(11;14) multiple myelomaLeukemia, 2017
- Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic ModelThe Journal of Clinical Pharmacology, 2017
- Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy VolunteersClinical Drug Investigation, 2016
- Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment categoryLeukemia, 2016
- Daratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine, 2016
- BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimeticsLeukemia, 2015
- ABT-737 is highly effective against molecular subgroups of multiple myelomaBlood, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The Bcl-2 apoptotic switch in cancer development and therapyOncogene, 2007
- Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosisBlood, 2001